FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2593171619> ?p ?o ?g. }

• W2593171619 endingPage "33036" @default.
• W2593171619 startingPage "33024" @default.
• W2593171619 abstract "// Chao-Chih Wu 2 , Fang-Cih Wu 2, 4 , Yun-Tin Hsu 2 , Yu-Chia Hsiao 2 , Yuh-Cheng Yang 1 , C. Allen Chang 4, 5 , Chih-Long Chang 1, 2, 3 1 Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei City, Taiwan 2 Departmental of Medical Research, Mackay Memorial Hospital, New Taipei City, Taiwan 3 Department of Medicine, Mackay Medical College, Sanchi, New Taipei City, Taiwan 4 Department of Biotechnology and Laboratory Science in Medicine, School of Biomedical Science and Engineering, National Yang-Ming University, Taipei City, Taiwan 5 Department of Biomedical Imaging and Radiological Sciences, School of Biomedical Science and Engineering, National Yang-Ming University, Taipei City, Taiwan Correspondence to: Chih-Long Chang, email: clchang@mmc.edu.tw C. Allen Chang, email: cachang@ym.edu.tw Keywords: DNA vaccine, BAFF Received: January 02, 2017     Accepted: February 13, 2017     Published: March 09, 2017 ABSTRACT B-cell-activating factor (BAFF) belongs to the tumor necrosis factor family that not only stimulates B and T cells but also counteracts immune tolerance. BAFF is also a type II membrane protein, which is secreted through the endoplasmic reticulum (ER)–Golgi apparatus pathway. Fusing an antigen to BAFF might enhance the presentation of major histocompatibility complex class I molecules. These characteristics represent an opportunity to enhance the antitumor effects of DNA vaccines. Therefore, we fused BAFF to human papillomavirus type 16 E7 as a DNA vaccine and evaluated its antitumor effects. We found that this vaccine increased E7-specific CD8 + T-cell immune responses, engendered major antitumor effects against E7-expressing tumors, and prolonged the survival of the immunized mice. Interestingly, vaccinating B-cell-deficient mice with BAFF–E7 revealed considerable E7-specific CD8 + T-cell immune responses, suggesting that B cells do not contribute to this immune response. Image analysis through confocal fluorescence microscopy revealed that fusing BAFF to E7 targeted the protein to the ER, but not BAFF lacking 128 N-terminal residues that generated a lower number of E7-specific CD8 + T cells in the vaccinated mice. Our data indicated that the ER-targeting characteristic of BAFF is the main factor improving the potency of DNA vaccines." @default.
• W2593171619 created "2017-03-16" @default.
• W2593171619 creator A5007456224 @default.
• W2593171619 creator A5010767483 @default.
• W2593171619 creator A5021534152 @default.
• W2593171619 creator A5048286805 @default.
• W2593171619 creator A5052424473 @default.
• W2593171619 creator A5072470505 @default.
• W2593171619 creator A5076759286 @default.
• W2593171619 date "2017-03-09" @default.
• W2593171619 modified "2023-09-27" @default.
• W2593171619 title "Enhanced anti-tumor therapeutic efficacy of DNA vaccine by fusing the E7 gene to BAFF in treating human papillomavirus-associated cancer" @default.
• W2593171619 cites W1537788154 @default.
• W2593171619 cites W1758242630 @default.
• W2593171619 cites W1970764748 @default.
• W2593171619 cites W1975953388 @default.
• W2593171619 cites W1983062261 @default.
• W2593171619 cites W2001778929 @default.
• W2593171619 cites W2012129419 @default.
• W2593171619 cites W2016313153 @default.
• W2593171619 cites W2030114892 @default.
• W2593171619 cites W2032348735 @default.
• W2593171619 cites W2037089018 @default.
• W2593171619 cites W2042923816 @default.
• W2593171619 cites W2047639703 @default.
• W2593171619 cites W2055186346 @default.
• W2593171619 cites W2061454749 @default.
• W2593171619 cites W2067930723 @default.
• W2593171619 cites W2071707918 @default.
• W2593171619 cites W2089938619 @default.
• W2593171619 cites W2090324342 @default.
• W2593171619 cites W2091687933 @default.
• W2593171619 cites W2095013915 @default.
• W2593171619 cites W2097968988 @default.
• W2593171619 cites W2105291234 @default.
• W2593171619 cites W2114941904 @default.
• W2593171619 cites W2115912718 @default.
• W2593171619 cites W2116902406 @default.
• W2593171619 cites W2119727082 @default.
• W2593171619 cites W2121076324 @default.
• W2593171619 cites W2127971170 @default.
• W2593171619 cites W2131207282 @default.
• W2593171619 cites W2135654435 @default.
• W2593171619 cites W2138229538 @default.
• W2593171619 cites W2144900828 @default.
• W2593171619 cites W2149449721 @default.
• W2593171619 cites W2155513663 @default.
• W2593171619 cites W2163972242 @default.
• W2593171619 cites W2167599930 @default.
• W2593171619 cites W2312909977 @default.
• W2593171619 cites W4205778255 @default.
• W2593171619 cites W4235081779 @default.
• W2593171619 doi "https://doi.org/10.18632/oncotarget.16032" @default.
• W2593171619 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5464847" @default.
• W2593171619 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28423693" @default.
• W2593171619 hasPublicationYear "2017" @default.
• W2593171619 type Work @default.
• W2593171619 sameAs 2593171619 @default.
• W2593171619 citedByCount "11" @default.
• W2593171619 countsByYear W25931716192017 @default.
• W2593171619 countsByYear W25931716192018 @default.
• W2593171619 countsByYear W25931716192020 @default.
• W2593171619 countsByYear W25931716192021 @default.
• W2593171619 countsByYear W25931716192022 @default.
• W2593171619 crossrefType "journal-article" @default.
• W2593171619 hasAuthorship W2593171619A5007456224 @default.
• W2593171619 hasAuthorship W2593171619A5010767483 @default.
• W2593171619 hasAuthorship W2593171619A5021534152 @default.
• W2593171619 hasAuthorship W2593171619A5048286805 @default.
• W2593171619 hasAuthorship W2593171619A5052424473 @default.
• W2593171619 hasAuthorship W2593171619A5072470505 @default.
• W2593171619 hasAuthorship W2593171619A5076759286 @default.
• W2593171619 hasBestOaLocation W25931716191 @default.
• W2593171619 hasConcept C126322002 @default.
• W2593171619 hasConcept C159654299 @default.
• W2593171619 hasConcept C167508917 @default.
• W2593171619 hasConcept C167672396 @default.
• W2593171619 hasConcept C170286685 @default.
• W2593171619 hasConcept C203014093 @default.
• W2593171619 hasConcept C2778453870 @default.
• W2593171619 hasConcept C2780801004 @default.
• W2593171619 hasConcept C2994532551 @default.
• W2593171619 hasConcept C502942594 @default.
• W2593171619 hasConcept C71924100 @default.
• W2593171619 hasConcept C8891405 @default.
• W2593171619 hasConceptScore W2593171619C126322002 @default.
• W2593171619 hasConceptScore W2593171619C159654299 @default.
• W2593171619 hasConceptScore W2593171619C167508917 @default.
• W2593171619 hasConceptScore W2593171619C167672396 @default.
• W2593171619 hasConceptScore W2593171619C170286685 @default.
• W2593171619 hasConceptScore W2593171619C203014093 @default.
• W2593171619 hasConceptScore W2593171619C2778453870 @default.
• W2593171619 hasConceptScore W2593171619C2780801004 @default.
• W2593171619 hasConceptScore W2593171619C2994532551 @default.
• W2593171619 hasConceptScore W2593171619C502942594 @default.
• W2593171619 hasConceptScore W2593171619C71924100 @default.
• W2593171619 hasConceptScore W2593171619C8891405 @default.
• W2593171619 hasIssue "20" @default.

• next